Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy
| Autor: | Chikage Iguchi, Tomoko Toga, Katsuhiro Tamura, Kunihiro Yamasawa, Ming Dong, Yoshinori Nio, Masayuki Itakura |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Pathology Pancreatic disease medicine.medical_treatment Statistics Nonparametric Immunoenzyme Techniques Pancreatic cancer Internal medicine Gene expression medicine Humans Survival analysis Aged Proportional Hazards Models Chemotherapy business.industry Antibodies Monoclonal General Medicine Middle Aged Ductal carcinoma medicine.disease Pancreatic Neoplasms Treatment Outcome medicine.anatomical_structure Proto-Oncogene Proteins c-bcl-2 Chemotherapy Adjuvant Immunohistochemistry Female Surgery Tumor Suppressor Protein p53 business Pancreas Carcinoma Pancreatic Ductal |
| Zdroj: | Journal of Surgical Oncology. 76:188-196 |
| ISSN: | 1096-9098 0022-4790 |
| DOI: | 10.1002/jso.1033 |
| Popis: | Background and Objectives p53 tumor suppressor gene has a dual role as a trigger of apoptosis and as an initiator of DNA repair. The Bcl-2 can work to protect cells from apoptosis, which is induced by p53 gene. These facts suggest the significant role of these genes in the genesis and progression of various tumors. The present study was designed to assess the significance of p53 and Bcl-2 protein (pBcl-2) expression on resectable invasive ductal carcinoma (IDC) of the pancreas. Methods The present study included 63 IDCs, which were resected between 1982 and 1998. pBcl-2 and p53 were stained immunohistochemically with monoclonal antibodies. Results pBcl-2 was expressed in 16 (25.4%), and p53 was positively expressed in 32 out of 63 IDCs (50.8%); however, expression of pBcl-2 did not necessarily correlate with that of p53. Although p53 expression did not show any significant influence on the patients' survival, pBcl-2(+) patients showed a higher survival than pBcl-2(−) patients for both p53(+) and p53(−) patients, which suggested that pBcl-2 expression had a more significant effect on the survival of patients than p53 expression. On the other hand, there were no differences in the survival curve between the adjuvant chemotherapy (ACT) group and the surgery alone (SA) group. pBcl-2 expression had no influence on the effect of ACT, the ACT group showed a significantly better survival than the SA group for p53(+) IDC patients. Conclusions pBcl-2 expression is a beneficial prognostic factor for patients with IDC, whereas p53 expression may be beneficial in the prediction of the effects of adjuvant chemotherapy on patients with IDC. J. Surg. Oncol. 2001;76:188–196. © 2001 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text